. 2022 Apr 13;10(2):e02235-21. doi: 10.1128/spectrum.02235-21

TABLE 2.

Antibacterial activity of IMR and other agents against preserved imipenem-nonsusceptible isolates

Species	No. of isolates	Antibacterial agent^a	MIC range (μg/mL)	No. (%) with MIC interpretation^b:
Species	No. of isolates	Antibacterial agent^a	MIC range (μg/mL)	Susceptible	Intermediate	Resistant
Escherichia coli	4	IMR	0.2 to 0.5	4 (100.0)	0	0
		Imipenem	2 to 8	0	2 (50.0)	2 (50.0)
		MEM	4 to 8	0	0	4 (100.0)
		TZP	128 to >128	0	0	4 (100.0)
		CAZ	128 to >128	0	0	4 (100.0)
		FEP	8 to >128	0	1 (25.0)^c	3 (75.0)
		LVX	16 to 32	0	0	4 (100.0)
		AMK	2 to 4	4 (100.0)	0	0
		CST	1	—^d	4 (100.0)	0
		TGC	0.25 to 0.5	4 (100.0)	—	0

Enterobacter cloacae complex	1	IMR	0.5	1 (100.0)	0	0
		Imipenem	8	0	0	1 (100.0)
		MEM	8	0	0	1 (100.0)
		TZP	>128	0	0	1 (100.0)
		CAZ	>128	0	0	1 (100.0)
		FEP	>128	0	0^c	1 (100.0)
		LVX	2	0	0	1 (100.0)
		AMK	1	1 (100.0)	0	0
		CST	1	—	1 (100.0)	0
		TGC	1	0	—	1 (100.0)

Klebsiella pneumoniae	3	IMR	0.5 to 16	1 (33.3)	1 (33.3)	1 (33.3)
		Imipenem	2 to 32	0	1 (33.3)	2 (66.7)
		MEM	16	0	0	3 (100.0)
		TZP	16 to >128	1 (33.3)	0	2 (66.7)
		CAZ	4 to >128	1 (33.3)	0	2 (66.7)
		FEP	1 to >128	1 (33.3)	0^c	2 (66.7)
		LVX	0.12 to >128	1 (33.3)	0	2 (66.7)
		AMK	2 to >128	2 (66.7)	0	1 (33.3)
		CST	0.5 to 1	—	3 (100.0)	0
		TGC	0.25 to 1	2 (66.6)	—	1 (33.3)

AMK, amikacin; FEP, cefepime; CAZ, ceftazidime; CST, colistin; IMR, imipenem/relebactam; LVX, levofloxacin; MEM, meropenem; TZP, tazobactam/piperacillin; TGC, tigecycline.

For TGC against Enterobacterales, EUCAST breakpoints in 2021 were applied because CLSI breakpoints were not defined.

Susceptible, dose-dependent.

—, Not applicable.